combined small cell lung carcinoma csclc form multiphasic lung cancer diagnosed pathologist malignant tumor arising transformed cells originating lung tissue contains component ofsmall cell lung carcinoma sclc admixed one components histological variant nonsmall cell lung carcinoma nsclc relative order ensure patients receive proper treatment critical pathologist making diagnosis lung cancer reports finding small cell carcinoma regardless components small cell carcinoma considered aggressive lung cancer variants treatment normally radically different forms lung cancer see epidemiological statistical purposes combined small cell carcinoma lung long classified subset small cell carcinoma subset component carcinoma sample lung cancer large exceptionally heterogeneous family different histological variants explicitly recognized within revision world health organization typing system currently widely used lung cancer classification many entities rare recently described poorly however since different forms malignant tumors generally exhibit diverse genetic biological clinical properties including response treatment accurate classification lung cancer cases critical assuring patients lung cancer receive optimum approximately lung cancers carcinoma term indicates malignant neoplasm composed descended cells epithelial lineage ie derived embryonic endoderm case lung carcinomas ectoderm andor malignant cells exhibit tissue architectural cytological molecular features characteristically found epithelial lung carcinomas divided major sclc generally considered aggressive major forms lung cancer worst long term prognosis survival result recommended multiphasic malignant lung tumors ie one histological pattern found contain proportion sclc cells classified csclc combined forms histological variants present currently exception recommendation occurs cases anaplastic large cell lung carcinoma lclc second histological component instances minimum viable malignant cells present must identified lclc tumor considered classification scheme csclc recognized variant exact mechanisms histogenesis lung cancers topics intense interest research currently thought cases lung cancer probably occur damage genomic dna causes malignant transformation single multipotent cell newly formed entity sometimes referred cancer stem cell begins divide uncontrollably giving rise new daughter cancer cells exponential near exponential fashion unless runaway cell division process checked clinically apparent tumor eventually form mass reaches sufficient size detected clinically begins cause signs approximately lung cancers eventually diagnosed histological variant carcinoma term signifies tumor derives transformed epithelial cells cells acquired epithelial characteristics result cell histogenesis csclc multiphasic forms lung cancer appear complex varied phenomena cases csclc genomic immunohistochemical studies suggest morphological divergence separate components occurs sclclike cell transformed cell potential develop nsclc variant characteristics vice versa daughter cells transdifferentiated sclclike cell repeatedly divide intrinsic genomic extrinsic environmental influences acquire additional mutations process known tumor progression result tumor acquires specific cytologic architectural features suggesting mixture sclc analyses suggest least cases highly differentiated variants nsclc ie adenocarcinoma progress give rise areas within primary original tumor metastases develop histological molecular characteristics molecular studies however suggest least minority cases independent development components csclc occurs via mutation transformation two different cells close spatial proximity due field cancerization cases repeated division mutational progression cancer stem cells generate biclonal collision regardless mechanisms give rise tumor recent studies suggest later stages csclc oncogenesis continued mutational progression within tumor component results cells combined tumor developing molecular profiles closely resemble cells pure forms individual morphological molecular oncogenetic convergence likely important implications treatment lesions given differences standard therapeutic regimens sclc nsclccitation needed csclc also occurs quite commonly treatment pure sclc chemotherapy andor radiation probably result combination tumor genomespecific progressional mutations stochastic genomic phenomena additional mutations induced cytotoxic common forms nsclc identified components within csclc large cell carcinoma adenocarcinoma squamous cell rarer variants nsclc seen less commonly combinations spindle cell giant cell giant cell carcinoma components seen much commonly patients undergone approval use newer molecularly targeted agents revealing differential efficacies specific subtypes variants nsclc becoming important pathologists correctly subclassify nsclcs distinct tumor entities components csclcscitation needed staging csclc patients usually performed analogous fashion patients pure small cell lung carcinoma several decades sclc staged according dichotomous distinction limited disease ld vs extensive disease ed tumor nearly clinical trials conducted sclc patients staged dichotomously ld roughly defined locoregional tumor burden confined one hemithorax encompassed within single tolerable radiation field without detectable distant metastases beyond chest supraclavicular lymph nodes patient assigned ed stage tumor burden greater defined ld criteria either far advanced locoregional disease malignant effusions pleura pericardium distant however recent data reviewing outcomes large numbers sclc patients suggests tnm staging system used nsclc also reliable valid applied sclc patients current versions may allow better treatment decisionmaking prognostication sclc old dichotomous staging large number clinical trials conducted pure sclc past several result evidencebased sets guidelines treating monophasic sclc current set sclc treatment guidelines recommend csclc treated manner pure sclc also note evidence supporting recommendation quite likely optimum treatment patients csclc remains current generally accepted standard care forms sclc concurrent chemotherapy ct thoracic radiation therapy trt ld ct ed complete responders patients evidence disease disappears prophylactic cranial irradiation pci also given trt serves increase probability total eradication residual locoregional disease pci aims eliminate micrometastases surgery often considered treatment option sclc including csclc due high probability distant metastases time paradigm driven early studies showing administration systemic therapies resulted improved survival compared patients undergoing surgical recent studies however suggested surgery highly selected earlystage csclc patients may indeed improve experts recommend resection residual masses nsclc components complete local tumor response chemotherapy andor radiotherapy although combinations drugs occasionally shown noninferior various endpoints subgroups patients combination cisplatin carboplatin plus etoposide irinotecan considered comparable firstline regimens patients respond first line therapy relapse complete remission topotecan agent definitively shown offer increased survival best supportive care although japan amrubicin considered effective salvage importantly csclc usually much resistant ct rt pure mechanisms increased resistance csclc conventional cytotoxic treatments highly active pure sclc remain mostly unknown recent studies suggest earlier biological history csclc treated likely resemble pure sclc response ct recent years several new types molecularly targeted agents developed used treat lung cancer large number agents targeting various molecular pathways developed tested main classes agents used lung cancer treatment date clinical trials targeted agents alone combination previously tested treatment regimens either ineffective sclc effective standard platinumbased randomized clinical trials targeted agents small case series suggest may useful csclc many targeted agents appear active certain nsclc variants given csclc contains components nsclc chemoradioresistance nsclc components impact effectiveness csclc treatment agents may permit design rational treatment regimens egfrtkis found active variants exhibiting certain mutations egfr egfr mutations rare pure sclc considerably common particularly nonsmoking females whose csclc tumors contain adenocarcinoma component patients much likely classical egfr mutations small cell component tumors well tumors seem likely respond treatment egfrtargeted agents appear particularly effective papillary nonmucinous bronchioloalveolar adenocarcinoma mixed role vegf inhibition bevacizumab treating sclc remains unknown studies suggest may combined agents improve measures survival sclc nonsquamous cell variants pemetrexed shown improve survival nonsquamous cell nsclc first drug reveal differential survival benefit large cell lung csclc appear express female hormone ie estrogen andor progesterone receptors high proportion cases similar breast however present unknown whether blockade receptors affects growth csclccitation needed current consensus longterm prognosis csclc patients determined sclc component tumor given pure sclc seems worst longterm prognosis forms lung although data csclc studies suggest survival rates csclc may even worse pure likely due lower rate complete response chemoradiation csclc although studies shown significant difference untreated pure sclc patients median survival time weeks months depending stage performance status time given proper multimodality treatment sclc patients limited disease median survival rates months patients extensive disease sclc although goodtocomplete responses treatment cured median survival evidence suggests csclc patients continue smoke may much worse outcomes treatment reliable comprehensive incidence statistics csclc unavailable literature frequency csclc variant diagnosed largely depends size tumor samples tending higher series large surgical resection specimens examined lower diagnoses based small cytology andor biopsy samples tatematsu et al reported cases csclc series consecutive sclc patients resection specimens contrast nicholson et al found csclc series consecutive resected sclc appears likely csclc variant comprises sclc incidence sclc declined somewhat us recent likely csclc also decreased incidence nevertheless small cell carcinomas including csclc variant still comprise lung cancers csclc probably accounting cases newly diagnosed lung cancer us year estimated study consecutive patients sclc quoix colleagues found presentation solitary pulmonary nodule spn particularly indicative csclc spns pathologically confirmed csclcs containing large cell carcinoma terms case numbers estimated csclc cases occurring annually us makes disease roughly comparable incidence hodgkins disease testicular cancer cervical cancer cancers larynx however four betterknown cancers exceptionally high cure rates contrast less csclc patients cured thus number annual cases csclc reasonable approximation annual number deaths therefore given significant incidence mortality attributable see prognosis survival arguably critical better understand aggressive lesions specific strategies management rationally however patients tumors containing mixtures histological subtypes usually excluded clinical properties multiphasic tumors like csclc much less well understood monophasic csclc contains sclc nsclc definition since patients sclc nsclc usually treated differently lack good data csclc means little evidence available form consensus whether csclc treated like sclc nsclc httpsenwikipediaorgwikicombinedsmallcelllungcarcinoma